Daniele Campolungo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniele Campolungo has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Beatrice Biferali
Gene Expression Regulation Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
2 shared publications - Davide Gabellini
Gene Expression Regulation Unit, Division of Genetics and Cell Biology, IRCCS Ospedale San Raffaele, Milan, Italy
2 shared publications - Mara Salomè
Paul O’Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
2 shared publications - Anna Sofia Tascini
Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy
1 shared publication Arianna Votta
Department of Biology, University of Pisa, Italy
1 shared publicationBeatrice Ciurli
Neurology Unit, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
1 shared publication
Latest Publications
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
The interferon-gamma response pathway is a targetable driver of FSHD muscular dystrophy progression
Facioscapulohumeral muscular dystrophy (FSHD) is a leading neuromuscular disorder caused by the aberrant expression of the transcription factor double homeobox 4 (DUX4) in skeletal muscle. While DUX4 is normally restricted to early embryonic development, its reactivation in FSHD triggers chronic inflammation and progressive muscle degeneration. However, the precise molecular links between DUX4 and persistent immune activation remain poorly understood. Here, we show that DUX4 induces a viral mimicry-like pathway that is fundamentally uncoupled from canonical type I interferon (IFN) activation. Instead, DUX4 establishes a non-canonical innate immune state dominated by IFN-γ signaling, providing a mechanistic explanation for the non-resolving inflammation characteristic of the disease. We demonstrate that while IFN-γ treatment alone is sufficient to recapitulate key DUX4 pathogenic effects, its inhibition rescues muscle inflammation and halts disease progression in FSHD models. These findings define a “skewed viral mimicry” process driven by a disease-specific transcription factor and identify IFN-γ as a primary therapeutic target for tissue-informed immunomodulation in muscular dystrophy.
- 20 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (47)
The interferon-gamma response pathway is a targetable driver of FSHD muscular dystrophy progression
Facioscapulohumeral muscular dystrophy (FSHD) is a leading neuromuscular disorder caused by the aberrant expression of the transcription factor double homeobox 4 (DUX4) in skeletal muscle. While DUX4 is normally restricted to early embryonic development, its reactivation in FSHD triggers chronic inflammation and progressive muscle degeneration. However, the precise molecular links between DUX4 and persistent immune activation remain poorly understood. Here, we show that DUX4 induces a viral mimicry-like pathway that is fundamentally uncoupled from canonical type I interferon (IFN) activation. Instead, DUX4 establishes a non-canonical innate immune state dominated by IFN-γ signaling, providing a mechanistic explanation for the non-resolving inflammation characteristic of the disease. We demonstrate that while IFN-γ treatment alone is sufficient to recapitulate key DUX4 pathogenic effects, its inhibition rescues muscle inflammation and halts disease progression in FSHD models. These findings define a “skewed viral mimicry” process driven by a disease-specific transcription factor and identify IFN-γ as a primary therapeutic target for tissue-informed immunomodulation in muscular dystrophy.
- Open Access
- 15 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (37) , eadi3771
DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia
Translocations producing rearranged versions of the transcription factor double homeobox 4 (DUX4-r) are one of the most frequent causes of B cell acute lymphoblastic leukemia (B-ALL). DUX4-r retains the DNA binding domain of wild-type DUX4 but is truncated on the C-terminal transcription activation domain. The precise mechanism through which DUX4-r causes leukemia is unknown, and no targeted therapy is currently available. We found that the rearrangement leads to both a loss and a gain of function in DUX4-r. Loss of CBP/EP300 transcriptional coactivator interaction leads to an inability to bind and activate repressed chromatin. Concurrently, a gain of interaction with the general transcription factor 2 I (GTF2I) redirects DUX4-r toward leukemogenic targets. This neomorphic activity exposes an Achilles’ heel whereby DUX4-r–positive leukemia cells are exquisitely sensitive to GTF2I targeting, which inhibits DUX4-r leukemogenic activity. Our work elucidates the molecular mechanism through which DUX4-r causes leukemia and suggests a possible therapeutic avenue tailored to this B-ALL subtype.
- 15 September 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (37) , eadi3771
Open AccessDUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia
Translocations producing rearranged versions of the transcription factor double homeobox 4 (DUX4-r) are one of the most frequent causes of B cell acute lymphoblastic leukemia (B-ALL). DUX4-r retains the DNA binding domain of wild-type DUX4 but is truncated on the C-terminal transcription activation domain. The precise mechanism through which DUX4-r causes leukemia is unknown, and no targeted therapy is currently available. We found that the rearrangement leads to both a loss and a gain of function in DUX4-r. Loss of CBP/EP300 transcriptional coactivator interaction leads to an inability to bind and activate repressed chromatin. Concurrently, a gain of interaction with the general transcription factor 2 I (GTF2I) redirects DUX4-r toward leukemogenic targets. This neomorphic activity exposes an Achilles’ heel whereby DUX4-r–positive leukemia cells are exquisitely sensitive to GTF2I targeting, which inhibits DUX4-r leukemogenic activity. Our work elucidates the molecular mechanism through which DUX4-r causes leukemia and suggests a possible therapeutic avenue tailored to this B-ALL subtype.